Language:

Daily summary of financings for therapeutic biotechnology company executives and investors

Collabrity Biopharma Private-PIPE Analysis

Thursday, February 5, 2026

Angitia’s $130 Million Series D

LB’s $100 Million Private Placement

Wednesday, February 4, 2026

Eikon’s $381 Million IPO…More

Chamber’s $60 Million Series A

Third Arc’s $52 Million Series A

Tuesday, February 3, 2026

Veradermics’s $256 Million IPO

Adlai’s $140 Million Private Placement

Sangamo’s $25 Million Public Offering

SonoVascular ‘s $6 Million Series A

Monday, February 2, 2026

Vaxcyte’s $632 Million Public Offering…More

Salspera’s $50 Million IPO

Friday, January 30, 2026

ProMIS’s $175 Million Private Placement

ALX’s $150 Million Public Offering

Lexicon’s $42 Million Public Offering and $53 Million Private Placement

Scilex’s $20 Million Equity Investment

Coya’s $11 Million Private Placement

Thursday, January 29, 2026

Agomab’s $829 Million IPO

Breakthru’s $60 Million Series A

Prenosis’s $20 Million Series A

PranaX’s $17 Million Series A

Aprea’s $6 Million Private Placement

Rakovina’s $1 Million Debt Financing

Enveric’s $1 Million Registered Direct Offering

Wedesday, January 28, 2026

Eikon’s $274 Million IPO

Cellares’s $257 Million Series D

Veradermics’s $200 Million IPO

Sensorion’s $72 Million Private Placement

CraniUS’s $20 Million Series B

Elysium’s $7 Million Fund Raise

Biomind’s $2 Million Private Placement

Tuesday, January 27, 2026

Epidarex’s $145 Million Fund Raise

Insilico’s $120 Million Venture Financing

Savara’s $75 Million Debt Financing

Altimmune’s $75 Million Registered Direct Offering

TRexBio’s $50 Million Venture Financing

BridGene’s $28 Million Series B+

Monday, January 26, 2026

Mirum’s $268 Million Acquisition of Bluejay

Fortitude’s $13 Million Seed Round…More

Barnwell’s $6 Million Seed Round

GentiBio’s Grant

Friday, January 23, 2026

Corvus’s $201 Million Public Offering…More

Spyre’s Grant

Thursday, January 22, 2026

CORXEL’s $287 Million Series D1

Axogen’s $124 Million Public Offering

Mendra’s $82 Million Series A

PAQ’s $77 Million Series B

Wednesday, January 21, 2026

Erasca’s $225 Million Public Offering…More

BioAge’s $115 Million Public Offering

Infinitopes’s $35 Million Seed Round

Ocugen’s $22 Million Public Offering

ErVimmune’s $20 Million Series A

BIOMAKERS’s $8 Million Fund Raise

L-Nutra’s $36 Million Series D

Kuva’s Acquisition of Lisata

Tuesday, January 20, 2026

GSK $2.2B Acquisition of RAPT Therapeutics

enGene’s $125 Million Debt Financing

4DMedical $100 Million Private Placement

Exciva’s $60 Million Series B

Think Bioscience’s $55 Million Series A

Friday, January 16, 2026

BridgeBio’s $550 Million Debt Financing

DBV’s $196 Million Warrant Exercise

Cytotheryx’s $60 Million Series A

Cardiol’s $13 Million Private Placement

Tiziana’s $9 Million Registered Direct Offering

MetaVia’s $9 Million Public Offering…More

Vivos’s $5 Million Warrant Exercise

Thursday, January 15, 2026

Boston Scientific’s $14 Billion Acquisiton of Penumbra

Agenus’s $141 Million Venture Financing

BriaCell’s $30 Million Public Offering

Wednesday, January 14, 2026

Caldera’s $112 Million Series A-1

Plus’s $15 Million Public Offering

Beyond’s $5 Million Private Placement

Tuesday, January 13, 2026

Nuclera’s $87 Million Series C

Proxima’s $80 Million Seed Round

Pelthos’s $50 Million Debt Financing

Foghorn’s $50 Million Registered Direct Offering

BriaCell’s $30 Million Public Offering

Converge’s $25 Million Series A

RISA’s $11 Million Series A

Vivere’s $10 Million Fund Raise

Enspire’s $10 Million Series B1

Monday, January 12, 2026

Mirador’s $250 Million Series B

Recludix’s $123 Million Equity Financing

Precede’s $83 Million Series B

Inquis’s $75 Million Series C

Oricell’s $70 Million Series C

Vibrant’s $61 Million Series B

Trailhead’s $40 Million Fund Raise

Juvena’s $33 Million Series B

Dogwood’s $27 Million Registered Direct Offering

OutSee’s $3 Million Seed Round

Saturday, January 10, 2026

Aktis’s $318 Million IPO

Kinaset’s $103 Million Series B

Friday, January 9, 2026

Orca’s $250 Million Series F

Haemonetics’s $215 Million Acquisition of Vivasure

AirNexis’s $200 Million Series A

Medipost’s $140 Million Fund Raise

Curis’s $81 Million Private Placement

Aptevo’s $60 Million Equity Investment

Clene’s $28 Million Registered Direct Offering

iBio $26 Million Private Placement

Aurora’s $16 Million Seed Round

Find’s $7 Million Series A

Thursday, January 8, 2026

Lily’s $1.2Billion Acquisition of Ventyx

Parabilis $305Million Series F

Monte Rosa’s $300 Million Public Offering

Alveus’s $160 Million Series A

Century’s $135 Million Private Placement

SonoThera’s $125 Million Series B

Diagonal’s $125 Million Series B

EpiBiologics’s $107 Million Series B

Beacon’s $75 Million Series C

Spruce’s $50 Million Debt Financing

Vizgen’s $48 Million Venture Financing

32 Biosciences’s $40 Million Series A

Engitix’s $25 Million Series A

Enodia’s $24 Million Fund Raise

Genelux’s $20 Million Public Offering…More

Muna’s $1 Million Grant

Wednesday, January 7, 2026

InduPro’s $950 Million Merger with Lilly

Arrowhead’s $500 Million Debt Financing

Soley’s $200 Million Series C
Bright Minds’s $175 Million Public Offering

Phathom’s $130 Million Public Offering

Nocion’s $93 Million Series B

Corsera’s $80 Million Series A

Mediar’s $76 Million Series B

Poplar’s $50 Million Series A

Collabrity Report 2025 – 2026,
All Rights Reserved

Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.

Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck  | Finalis Form Customer Relationship Summary (“Form CRS”)

collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.

Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.